Table 1.

Patient baseline characteristics

	Entire patient cohort	Transplant eligible and received auto-HCT	Transplant eligible and received allo-HCT	Transplant eligible but did not receive transplant	Transplant ineligible because of comorbidities or age	P value
N	207 (100%)	86 (42%)	12 (6%)	63 (22%)	46 (30%)
Age (y) at diagnosis, median (range)	58 (33-88)	57 (33-69)	54 (36-64)	58 (41-69)	62 (37-88)	<.001
Ki67, median, % (range)	70 (0-100)	67 (0-100)	60 (10-90)	75 (20-100)	70 (10-100)	.53
MIPI score
MIPI low, n (%)	68 (32)	33 (38)	7 (58)	19 (30)	9 (20)	<.001
MIPI intermediate, n (%)	38 (18)	23 (27)	1 (9)	8 (13)	6 (13)	<.001
MIPI high, n (%)	51 (25)	12 (14)	2 (16)	16 (25)	21 (46)	<.001
MIPI missing data, n (%)	51 (24)	18 (21)	2 (17)	20 (31)	10 (22)	<.001
Male sex, n (%)	163 (79)	73 (85)	9 (75)	48 (76)	33 (72)	.30
TP53 abnormalities	13 (7.8)	5 (6.8)	2 (22)	2 (4.1)	4 (11.4)	.17
Stage IV, n (%)	173 (84)	76 (88)	10 (83)	49 (80)	38 (83)	.80
Treatment characteristics
CHOP induction, n (%)	75 (36)	23 (27)	3 (25)	22 (35)	27 (60)	.003
Intensive induction∗, n (%)	113 (55)	60 (70)	8 (67)	33 (52)	12 (27)	.003
Bendamustine induction, n (%)	16 (8)	3 (3)	1 (8)	7 (11)	5 (11)	.003
Cytarabine-containing induction, n (%)	110 (53)	61 (71)	7 (58)	31 (49)	11 (24)	<.001
Rituximab-containing induction, n (%)	186 (89)	79 (92)	11 (92)	59 (94)	37 (82)	.22
Rituximab maintenance after induction, n (%)	184 (88)	81 (94)	12 (100)	54 (86)	37 (80)	.72
Response to induction
CR as best response, n (%)	140 (69)	73 (85)	7 (58)	45 (71)	15 (35)	.001
PR as best response, n (%)	38 (19)	13 (15)	5 (42)	17 (27)	3 (7)	.001
SD or PD as best response, n (%)	25 (12)	1 (1)	0 (0)	0 (0)	24 (56)	.001

auto-HCT, autologous hematopoietic cell transplantation; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

^∗Intensive induction refers to hyperCVAD-, maxi-CHOP–, or DHAP-based inductions.